1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma
    Meeting Abstract

    Richter, J. R.; Landgren, C. O.; Kauh, J. S.; Back, J.; Salhi, Y.; Reddy, V.; Bayever, E.; Berdeja, J. G.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Baseline demographics and disparities in cancer registration trials: An analysis of US Food and Drug Administration approved drugs in 2015 and 2016
    Meeting Abstract

    Maniar, R.; Green, A.; Bach, P.; Mailankody, S.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Molecular underpinnings of clinical disparity patterns in African American (AA) versus Caucasian American (CA) multiple myeloma (MM) patients
    Meeting Abstract

    Hill, E. M.; Kwok, M.; Yellapantula, V.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Papaemmanuil, E.; Maric, I.; Kazandjian, D. G.; Landgren, O.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study
    Meeting Abstract

    Biran, N.; Di Capua Siegel, D. S.; Berdeja, J. G.; Raje, N. S.; Cornell, R. F.; Alsina, M.; Kovacsovics, T.; Fang, B.; Kimball, A.; Landgren, C. O.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Addendum: Low-value approvals and high prices might incentivize ineffective drug development
    Journal Article

    Prasad, V.; McCabe, C.; Mailankody, S.
    Nature Reviews Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Circulating immunologic markers and risk of multiple myeloma and its precursor disease: A nested case-control study
    Meeting Abstract

    Hofmann, J. N.; Landgren, O.; Katki, H.; Kemp, T.; Santo, L.; McShane, C.; Lan, Q.; Rothman, N.; Pinto, L.; Pfeiffer, R.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Nrf2-mediated oxidative stress response is altered during acquired resistance to the proteasome inhibitor, oprozomib, in multiple myeloma
    Meeting Abstract

    Gaikwad, S. M.; Zingone, A.; Michalowski, A.; Najera, S.; Quintanilla-Artega, A.; Gorjifard, S.; Simmons, J.; Watson, N.; Landgren, O.; Huang, J.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Donor-specific antibodies, immunoglobulin-free light chains, and BAFF levels in relation to risk of late-onset PTLD in liver recipients
    Journal Article

    Engels, E. A.; Jennings, L. W.; Everly, M. J.; Landgren, O.; Murata, K.; Yanik, E. L.; Pfeiffer, R. M.; Onaca, N.; Klintmalm, G. B.
    Transplantation Direct (2018)

    Fulltext@MSK | Save
  • CAR T cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D), a novel target for the immunotherapy of multiple myeloma
    Meeting Abstract

    Smith, E. L.; Harrington, K.; Staehr, M.; Masakayan, R.; Jones, J.; Long, T.; Ghoddusi, M.; Purdon, T. J.; Do, T.; Wang, X.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save